Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference
December 01 2022 - 6:00AM
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a
biotechnology company focused on developing and commercializing
genetic medicines for patients with rare diseases, announced today
that the Company will participate in the BofA Securities 2022
Biotech SMID Cap Conference, which is taking place virtually from
December 7-8.
Krish S. Krishnan, Chairman and Chief Executive Officer, will
participate in a fireside chat during the conference and host
investor meetings on December 7.
A live audio webcast of the presentation will be available here
at 2:20 pm ET on Wednesday, December 7 and an archived version of
the webcast will be available following the presentation on the
Investor section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a biotechnology company
focused on developing and commercializing genetic medicines for
patients with rare diseases. The Company’s wide-ranging pipeline is
based on its proprietary redosable HSV vector. Headquartered in
Pittsburgh, Pennsylvania, the Company is led by an experienced
management team, is fully-integrated and has core capabilities in
viral vector design, vector optimization, gene therapy
manufacturing and commercialization. For more information, please
visit http://www.krystalbio.com, and follow @KrystalBiotech on
LinkedIn and Twitter.
CONTACT:
Investors and MediaMeg DodgeKrystal
Biotechmdodge@krystalbio.comSource: Krystal Biotech, Inc.
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Jul 2023 to Jul 2024